Legal & General Group Plc Decreases Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK)

Legal & General Group Plc decreased its position in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) by 5.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 35,347 shares of the company’s stock after selling 2,139 shares during the quarter. Legal & General Group Plc owned 0.07% of Stoke Therapeutics worth $390,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. KLP Kapitalforvaltning AS purchased a new stake in Stoke Therapeutics in the 4th quarter valued at approximately $63,000. Teacher Retirement System of Texas purchased a new stake in shares of Stoke Therapeutics during the 4th quarter worth about $113,000. China Universal Asset Management Co. Ltd. acquired a new position in Stoke Therapeutics during the 4th quarter worth approximately $124,000. Invesco Ltd. acquired a new position in Stoke Therapeutics during the 4th quarter worth approximately $133,000. Finally, Wells Fargo & Company MN lifted its position in Stoke Therapeutics by 51.2% during the 4th quarter. Wells Fargo & Company MN now owns 16,786 shares of the company’s stock worth $185,000 after acquiring an additional 5,682 shares in the last quarter.

Stoke Therapeutics Stock Performance

Shares of STOK opened at $9.76 on Thursday. Stoke Therapeutics, Inc. has a one year low of $5.35 and a one year high of $17.58. The firm has a market capitalization of $532.87 million, a price-to-earnings ratio of -4.65 and a beta of 1.09. The stock’s fifty day moving average is $7.84 and its 200-day moving average is $10.24.

Stoke Therapeutics (NASDAQ:STOK) last released its earnings results on Monday, March 24th. The company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.38. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. The business had revenue of $22.61 million for the quarter, compared to the consensus estimate of $4.20 million. Analysts forecast that Stoke Therapeutics, Inc. will post -2.01 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on STOK shares. Chardan Capital reaffirmed a “buy” rating and issued a $24.00 target price on shares of Stoke Therapeutics in a research report on Wednesday, March 19th. HC Wainwright reaffirmed a “buy” rating and issued a $47.00 target price on shares of Stoke Therapeutics in a research report on Wednesday, March 19th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $22.00 target price on shares of Stoke Therapeutics in a research report on Wednesday, April 9th. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $24.67.

Insider Transactions at Stoke Therapeutics

In related news, Director Edward M. Md Kaye sold 10,382 shares of the business’s stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total transaction of $90,011.94. Following the transaction, the director now directly owns 148,253 shares of the company’s stock, valued at approximately $1,285,353.51. The trade was a 6.54 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Barry Ticho sold 3,884 shares of the business’s stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total transaction of $33,674.28. Following the transaction, the insider now directly owns 63,962 shares in the company, valued at $554,550.54. The trade was a 5.72 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 16,532 shares of company stock valued at $143,332 over the last ninety days. Corporate insiders own 11.30% of the company’s stock.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.